RIGEL PHARMACEUTICALS INC

$40m committed across 1 active facility. RIGL

Pharmaceutical Preparations

CovenantTestedHeadroomLimit now

Tested springingHeadroom not yet measuredn/a

No source quote on file for this covenant.

Read the filing on sec.gov ↗

Tested otherHeadroom not yet measuredn/a

No source quote on file for this covenant.

Read the filing on sec.gov ↗

Download CSV · Download JSON

AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENTunconfirmed

Signed May 5, 2026

Committed: $40m
Matures: May 2031
Agent: MidCap Funding IV Trust

Tranche	Size	Matures	Margin
Revolving Loan Facility	$40m	May 2031	400 bps

Priced over Term SOFR (Revolving credit facility).

Level	Condition	Margin	Unused fee
Level Level 1	all times	400 bps	n/a

May 11, 2026
Amendment
Amendment No. 1 permits Rigel to enter into the Arvinas License Agreement and make Arvinas Payments, and adds related definitions. It also amends the Material Contracts list, expands Permitted Investments to include the Arvinas transaction, and revises Permitted Contingent Obligations to allow Arvinas Payments subject to no Specified Event of Default and covenant compliance.
- definitions.arvinas_license_agreement: n/a → n/a §Section 2(a)
- definitions.first_amendment: n/a → n/a §Section 2(b)
- definitions.first_amendment_effective_date: n/a → 2026-05-11 §Section 2(c)
- definition.material_contracts: n/a → n/a §Section 2(e)
- definition.permitted_investments: n/a → n/a §Section 2(f)
- definition.permitted_contingent_obligations: n/a → n/a §Section 2(g)
Filing ↗

Report an error

Email [email protected].